Literature DB >> 2845993

Adriamycin and its iron(III) and copper(II) complexes. Glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin.

B B Hasinoff1, J P Davey.   

Abstract

Some reactions of adriamycin (doxorubicin) and its Fe3+ and Cu2+ complexes were investigated with a view to understanding the mechanisms by which metal ion-adriamycin complexes damage cellular components. The ability of adriamycin in the presence of Cu2+ to inactivate the mitochondrial enzyme cytochrome c oxidase was effectively prevented by physiologic levels of glutathione. This result is explained by the observation that glutathione reacts with the Cu2+-adriamycin complex to produce free adriamycin. As sulfhydryl compounds are, in contrast, known to promote Fe3+-adriamycin-induced damage to cellular components, these results suggest that the response of a metal ion-adriamycin system to the presence of sulfhydryl compounds may be indicative of whether or not Cu2+-adriamycin is the damaging species. The partition of adriamycin into the octanol phase of an octanol-water two-phase system was greatly enhanced by the presence of cardiolipin. This result can be explained by the formation of a strong adriamycin-cardiolipin complex in the octanol phase which is one-half formed at an adriamycin concentration of 6 microM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845993     DOI: 10.1016/0006-2952(88)90399-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Polyplex Evolution: Understanding Biology, Optimizing Performance.

Authors:  Arnaldur Hall; Ulrich Lächelt; Jiri Bartek; Ernst Wagner; Seyed Moein Moghimi
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

2.  Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.

Authors:  Anne M Traynor; James P Thomas; Ramesh K Ramanathan; Tarak D Mody; Dona Alberti; George Wilding; Howard H Bailey
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

3.  The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.

Authors:  J L Buss; B B Hasinoff
Journal:  Agents Actions       Date:  1993-09

4.  The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1990-03

5.  The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1989-03

Review 6.  Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy.

Authors:  Zijian Zhou; Jibin Song; Liming Nie; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-11-21       Impact factor: 54.564

7.  Inhibition and inactivation of NADH-cytochrome c reductase activity of bovine heart submitochondrial particles by the iron(III)-adriamycin complex.

Authors:  B B Hasinoff
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

8.  Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes.

Authors:  Baikuntha Aryal; V Ashutosh Rao
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

Review 9.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989

10.  Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells.

Authors:  Xi Chen; Xiaoming Chen; Xi Zhang; Li Wang; Peihai Cao; Vinothkumar Rajamanickam; Chao Wu; Huiping Zhou; Yuepiao Cai; Guang Liang; Yi Wang
Journal:  Redox Biol       Date:  2018-12-07       Impact factor: 11.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.